Scholar Rock Holding Corporation (SRRK)

Market Cap	5.65B +76.5%
Revenue (ttm)	n/a
Net Income	-377.94M
EPS	-3.48
Shares Out	114.88M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,317,523
Open	49.34
Previous Close	49.99
Day's Range	48.56 - 50.00
52-Week Range	22.71 - 51.63
Beta	0.69
Analysts	Strong Buy
Price Target	55.64 (+13.11%)
Earnings Date	May 13, 2026

About SRRK

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company’s novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFβ) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or laten...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 24, 2018
• Employees: 289
• Stock Exchange: NASDAQ
• Ticker Symbol: SRRK
• Website: https://www.scholarrock.com

Analyst Summary

According to 12 analysts, the average rating for SRRK stock is "Strong Buy." The 12-month stock price target is $55.64, which is an increase of 13.11% from the latest price.

Price Target

$55.64

(13.11% upside)

Analyst Consensus: Strong Buy